PureTech Health PLC Additional Listing (6797S)
June 27 2018 - 2:00AM
UK Regulatory
TIDMPRTC
RNS Number : 6797S
PureTech Health PLC
27 June 2018
PureTech Health plc
Block listing Application
PureTech Health plc ("PureTech Health" or "the Group") (LSE:
PRTC) announces that an application has been made to the Financial
Conduct Authority and the London Stock Exchange for admission to
(i) the Premium segment of the Official List and (ii) to trading on
the London Stock Exchange for a block listing of 250,000 ordinary
shares of 1 pence each (the "Ordinary Shares").
The Ordinary Shares are being reserved under a block listing and
will be issued from time to time pursuant to the PureTech
Performance Share Plan.
It is expected that admission of the Ordinary Shares will become
effective on 29 June 2018. The Ordinary Shares will rank pari passu
in all respects with the Group's existing ordinary shares in
issue.
About PureTech Health
PureTech Health (PRTC.L) is an advanced, clinical-stage
biopharmaceutical company developing novel medicines targeting
serious diseases that result from dysfunctions in the nervous,
immune, and gastrointestinal systems (brain-immune-gut or the "BIG"
axis), which together represent the adaptive human systems.
PureTech Health is at the forefront of understanding and addressing
the biological processes and crosstalk associated with the BIG
axis. By harnessing this emerging field of human biology, PureTech
Health is pioneering new categories of medicine with the potential
to have great impact on people with serious diseases. PureTech
Health is advancing a rich pipeline of innovative therapies that
includes two pivotal stage programmes, multiple human
proof-of-concept studies and a number of early clinical and
pre-clinical programmes. PureTech's research and development
pipeline has been advanced in collaboration with some of the
world's leading scientific experts, who along with PureTech's team
of biopharma pioneers, entrepreneurs and seasoned Board, identify,
invent, and clinically de-risk new medicines. With this experienced
team pursuing cutting edge science, PureTech Health is building the
biopharma company of the future focused on improving and extending
the lives of people with serious disease. For more information,
visit www.puretechhealth.com or connect with us on Twitter
@puretechh.
Contact:
Investors
Allison Mead Talbot
+1 617 651 3156
amt@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ALSGMGZVGVVGRZZ
(END) Dow Jones Newswires
June 27, 2018 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024